Group 1 - The core point of the article highlights that the Silverhua Science and Technology Bond ETF (159112.SZ) experienced a slight increase of 0.05% on December 19, 2025, despite significant net outflows of 2.419 billion yuan from major funds (transactions over 1 million yuan) [1] - The latest trading volume for the fund was reported at 38.9235 million units, with the total transaction amount falling below 3.9 billion yuan, placing it at the lower end among comparable funds [1]

Core Viewpoint - The article discusses the trend of public funds hiring managers with pharmaceutical backgrounds to enhance their portfolios, particularly in the context of a market correction in the innovative drug sector as the year-end approaches [1][2]. Group 1: Hiring Trends - Several non-pharmaceutical themed funds have recently announced the hiring of managers with pharmaceutical expertise, indicating a shift towards a more balanced investment strategy [2][3]. - The hiring of these managers is seen as a response to the need for diversified portfolio management amid increasing market volatility and sector rotation [5][6]. Group 2: Fund Examples - Silver华 Fund announced the hiring of Wu Ying, a manager with a strong pharmaceutical background, for its Silver华乐享生活 mixed fund, which previously focused heavily on semiconductor stocks [3][4]. - Similarly, Ping An Fund appointed Fang Junping, another pharmaceutical investment veteran, to co-manage its Ping An Balanced Selection mixed fund, which had a predominant focus on real estate stocks [4][5]. Group 3: Market Outlook - The hiring of pharmaceutical managers is driven by expectations of a sustained uptrend in the pharmaceutical sector, with a focus on the upcoming performance of Chinese pharmaceutical companies [7][8]. - Analysts predict that 2026 will be a pivotal year for innovative drugs, with potential for both earnings and valuation expansion, as many companies are expected to release significant clinical data [7][8].

专题：2025第9届"银华基金杯"新浪·理财师大赛 12月11日，第九届"银华基金杯"新浪理财师大赛全国总决赛在北京举行，新浪财经执行总编辑王婷婷出席并发表致辞。她表示，伴随着内外环境的深刻变 革，行业正式进入"专业致胜、服务升级"的关键阶段 ，如何把握经济转型中的投资机遇、精准匹配投资者需求、实现专业与服务双提升，成为行业核心课 题，更对理财师在宏观研判、资产配置、风险管控、客户服务等方面的综合素养提出了极高要求。 新浪财经执行总编辑王婷婷致辞 王婷婷指出，理财师的价值不止于数字计算与产品推荐，更在于以专业为投资者护航，以服务传递温度，实现风险与收益平衡——这正是大赛"专业赋能价 值，服务传递温度"的核心理念。 以下为王婷婷致辞原文： 尊敬的苏薪茗苏总、各位评委老师、各位嘉宾、所有的参赛选手： 大家好。 欢迎各位来到由新浪财经和银华基金联合主办的2025第9届"银华基金杯"新浪·理财师大赛全国总决赛现场。我谨代表新浪财经，向莅临现场的评委、嘉宾致 以诚挚欢迎，向合作伙伴银华基金以及长期支持大赛的所有机构表示衷心感谢！ 2025年，中国经济在稳增长政策持续发力下，始终保持 "稳中有进、质效提升" 的良好态势。 ...

专题：2025第9届"银华基金杯"新浪·理财师大赛 12月11日，第九届"银华基金杯"新浪理财师大赛全国总决赛在北京举行，随着总决赛的圆满落幕，个人赛及团队赛的冠、亚、季军诞生！ 今年全国总决赛，从比赛形式上有所升级，区别于往届，本次使用开放性命题，让选手有更多选择和方向，也同时考验选手的知识储备和现场应答能力。 个人赛分为 "理财开放麦"和"拜托了，理财师"两个环节。 "理财开放麦"环节，要求选手自拟理财话题，从亲身经历、宏观环境、自我观点等多角度出发， 讲述理财、投教相关内容。"拜托了，理财师"将现场抽取情景案例题目，根据理财需求给出理财建议。 团队赛分为"理财方案设计赛"和"巅峰辩论赛"两个环节。"理财方案设计赛"环节要求理财团队自拟一个目标人群和理财需求，为他制定一个理财方案， 不设 主题方向和产品。"巅峰辩论赛"则是10支团队就当下热点投资话题两两辩论。 最终，个人赛中，来自交通银行齐齐哈尔分行的怀迎吉获得全国冠军，中国邮政储蓄银行江西省分行的卢晓丽获得全国亚军，中国建设银行岳阳分行的王妍 和北京银行中关村分行的段江洋并列全国季军，来自北京银行上海分行的高聪聪、渤海银行北京分行的钱磊、中国建设银行河 ...

Core Viewpoint - The recent adjustment in the Hong Kong stock market has led to a surge in new fund issuance, with many funds shortening their fundraising periods to capitalize on the market dip, indicating a strong belief in the investment value of Hong Kong stocks [1][5]. Fund Issuance Trends - New funds are significantly shortening their fundraising periods compared to previous practices, with examples including the 富国港股精选混合 fund, which moved its deadline from December 19 to December 10, raising 1.83 billion yuan [2]. - Other funds, such as 鹏扬基金 and 路博迈基金, have also adjusted their fundraising timelines, reflecting a broader trend of rapid fundraising in the current market environment [2]. Rapid Fund Deployment - New funds are not only closing fundraising early but are also quickly building their positions in the market. For instance, the 汇添富恒指港股通ETF achieved a 69.53% stock position just a week before its listing [3]. - This contrasts with previous cautious strategies where funds maintained low positions prior to listing, indicating a shift in approach due to market conditions [3]. Market Sentiment and Strategy Adjustments - The adjustment in fundraising strategies is driven by significant market corrections, with many funds seizing the opportunity to invest in fundamentally strong companies despite recent price declines [4]. - The rapid changes in fundraising strategies, such as those seen with 鑫元基金, highlight the dynamic nature of market conditions and the urgency to capture rebound opportunities [4]. Positive Outlook on Hong Kong Stocks - Multiple fund managers express optimism about the Hong Kong market, viewing the current adjustments as a favorable entry point for future growth, particularly in sectors like AI, internet, and innovative pharmaceuticals [5][6]. - The valuation of the 恒生科技指数 is noted to be significantly lower than that of comparable indices, suggesting a high potential for returns [5]. - Specific sectors identified for investment include technology growth, financial services, and cyclical stocks, indicating a strategic focus on areas with perceived value [5].

Core Insights - The public funds in A-shares have seen significant profits from private placements this year, with 39 public institutions participating in 85 A-share companies, accumulating a total allocation of 34.088 billion yuan, a year-on-year increase of 14.24% [1][3] - As of December 17, the floating profit from public fund private placements reached 11.224 billion yuan, with an overall floating profit ratio of 32.93% [1][3] Participation and Performance - Among the 39 public institutions involved in A-share private placements, 29 were particularly active, each participating with allocations of at least 100 million yuan, with 24 institutions receiving between 10 million to 99.9 million yuan, and 5 institutions exceeding 1 billion yuan [1][3] - Nord Fund emerged as the leader in public fund private placements, participating in 80 A-share placements with a total allocation of 10.173 billion yuan, followed by Caitong Fund with 9.851 billion yuan from 76 placements, and E Fund with 2.961 billion yuan from 11 placements [1][3] Profitability Analysis - Out of the 39 public institutions, 37 achieved floating profits, representing a high ratio of 94.87%. Among these, 19 institutions had floating profit ratios within 20%, 12 institutions between 20% and 49.99%, and 6 institutions exceeding 50% [2][4] - Specific examples include Nuon Fund's participation in Chip Original's private placement with a floating profit ratio of 80.81% and Yinhua Fund's participation in Zhongke Feimiao's private placement with a floating profit ratio of 73.60% [2][4] Market Outlook - Industry insiders believe that the professional research capabilities and capital scale advantages of public funds allow them to take the initiative in the private placement market. Their active participation reflects a keen capture of market opportunities and indicates an optimization of the private placement market ecosystem, suggesting sustained enthusiasm for institutional participation in the future [5]

四、12月17日基金分红一览 （1）12月17日新发基金共有5只，主要为基金中的基金(FOF)基金和混合型基金，其中鑫元鑫选多元稳进配置3个月持有期 混合(FOF)A募集目标金额达50.00亿元；基金分红24只，多为债券型，派发红利最多的基金是前海开源沪深300指数型证券 投资基金，每10份基金份额派发红利2.5000元。 （2）2025年行情进入收官阶段，量化私募全面回暖。数据显示，截至11月底，股票量化多头策略年内平均超额收益达 17.25%，行业管理规模同步攀升，已接近历史高位。业内人士指出，从因子挖掘、组合优化到交易执行，AI技术正深度嵌 入量化全流程，显著放大策略容量与迭代速度，竞争格局被重新书写；随着性能持续提升，头部机构有望借助技术红利进 一步巩固领先优势，行业集中度或继续抬升。 （3）临近收官，2025年新基金发行节奏图浮出水面：下半年募集周期较上半年显著压缩，平均认购天数明显减少，"日光 基"数量大幅增加。业内人士指出，市场氛围回暖、资金配置需求集中释放，为发行提速提供土壤，基金公司顺势缩短募集 期、加快建仓，抢占年末配置窗口，预计这一趋势有望延续至明年春季。 三、12月17日新发基金一览（ ...

Group 1 - The Hong Kong stock market has experienced a continuous adjustment, leading to a surge in new fund issuance with shortened fundraising periods and opportunistic investments [1][5] - Several new Hong Kong-themed funds have announced early closures of their fundraising periods, indicating a strong desire to capitalize on the market's recent downturn [2][4] - Fund managers believe that the current market correction provides a favorable window for new funds to establish positions, given the high allocation value of Hong Kong stocks [1][5] Group 2 - Recent new funds have significantly shortened their fundraising periods, with some funds achieving substantial subscription amounts despite limited time for investor participation [2][3] - Notable examples include the 富国港股精选混合 fund, which raised 1.83 billion yuan in a shortened period, and other funds that have similarly adjusted their timelines [2] - The trend of rapid fundraising is also seen in public fund-of-funds (FOF) products, which are adjusting their strategies to invest in Hong Kong stocks [2] Group 3 - Many new funds are engaging in "lightning" investments, rapidly building positions in major stocks like Alibaba and Tencent ahead of their official listing dates [3] - The high pre-listing investment ratios of these funds contrast sharply with previous months, indicating a shift in strategy driven by recent market volatility [3] - Fund managers attribute this aggressive investment approach to the significant price drops in key stocks, despite their strong fundamentals [3] Group 4 - Some funds have adjusted their fundraising strategies in response to market fluctuations, as seen with 鑫元基金, which changed its fundraising deadline multiple times [4] - The adjustments reflect a proactive approach to market conditions, allowing funds to capitalize on opportunities as they arise [4] Group 5 - Fund managers express optimism about the Hong Kong market's prospects for 2026, viewing it as a key channel for foreign investment in Chinese core assets [5][6] - The current valuation of the Hang Seng Technology Index is considered attractive compared to other markets, suggesting a favorable risk-reward profile for investors [6] - Key investment themes include AI infrastructure, internet technology, and cyclical stocks, with a focus on sectors that are expected to benefit from ongoing market reforms and technological advancements [6]

银华基金用124个公益项目、近3300万元真金白银的投入，在金融与公益的交会地带开辟出一条独具特 色的"责任航道"。 即使是扶贫济困的公益项目，银华基金的公益实践也不会简单直接地拨款。例如在内蒙古兴和县的饮水 工程中，银华基金经过详细调研，将资金精准定向用于搭建24小时自来水供水试点，切实解决村民"靠 天吃水"的困境。 此外，银华基金还积极开展水灾、地震等自然灾害以及重大公共卫生事件救援救助，通过捐赠资金和急 需物资等，协助相关单位和群众共同抗灾抢险，减少重大公共卫生事件影响，帮助群众尽快恢复生产生 活。 "路漫漫其修远兮，吾将上下而求索"。近年来，银华基金积极践行企业的社会责任，并依托金融行业优 势，在救灾扶困、乡村振兴、教育扶贫等各个层面展开实际行动。截至今年8月，银华公益基金会累计 实施公益项目124个，对外捐助金额近3300万元。 日前，2025年第一财经·中国企业社会责任典范评选榜单揭晓，银华基金凭借在防沙治沙、助学助教、 公益慈善等社会责任方面的多维探索，从众多参选机构中脱颖而出，获得了"可持续责任典范"评价。 作为服务大众理财需求的公募基金公司，银华基金将教育公益置于其社会责任版图的核心位置，其 ...

Core Viewpoint - The launch of the China Drug Price Registration System is expected to accelerate the internationalization of Chinese innovative drugs by providing a global, authoritative, standardized, and transparent market price registration platform [1] Group 1: Overview of the Drug Price Registration System - The China Drug Price Registration System is a national-level price registration platform independent of the medical insurance network, offering services such as price registration, price inquiry, price comparison, and notarization [2][8] - Pharmaceutical companies can autonomously declare and register drug prices based on their development needs, ensuring the authenticity of the submitted information, while the operating unit only processes registration applications without interfering with pricing [2][8] Group 2: Impact on Chinese Innovative Drugs - The system aims to address the pricing challenges faced by Chinese innovative drugs in international markets, which have been hindered by reliance on medical insurance negotiation prices that may undervalue these products [3][9] - The establishment of a "one drug, one file" database will provide authoritative pricing references for companies, facilitating the construction of a consistent pricing system for domestic and international markets [3][9] Group 3: Four Major Impacts on Domestic Innovative Drugs - Accelerating Internationalization: In the first three quarters of 2025, Chinese pharmaceutical companies completed over 103 overseas licensing transactions, with a total transaction value exceeding $92 billion, highlighting the increasing reference value of China's terminal prices [6][12] - Enhancing Commercial Certainty: The system operates independently from provincial medical procurement platforms, allowing companies to declare prices applicable to various healthcare settings, including private hospitals and self-funded medical services [6][13] - Attracting Multinational Pharmaceutical Companies: The system not only supports the international expansion of Chinese innovative drugs but also attracts high-quality foreign drugs to the Chinese market, enhancing competition [6][13] - Promoting Healthy Competition and Innovation Incentives: The market identity associated with the declared prices reflects the clinical value of innovative drugs, enabling companies to achieve higher returns in non-medical insurance markets, thus fostering a positive cycle of research and development [6][13]